New CARMELINA Analysis: No Heart Failure Risk With Linagliptin New CARMELINA Analysis: No Heart Failure Risk With Linagliptin

A secondary analysis of CARMELINA trial data with linagliptin underlines that DDP-4 inhibitors are not linked to an increase in heart failure outcomes in patients with type 2 diabetes, say US researchers.Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news